Prostate Health Index (phi)
ورودیهای بالینی بیمار
حداقل ۲ — حداکثر ۱۰
حداقل ۰.۱ — حداکثر ۱۰
حداقل ۱ — حداکثر ۵۰۰۰
حداقل ۵۰ — حداکثر ۱۰۰
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Below operating point0–27
- At/above operating point27–1000000000
The Prostate Health Index (phi) calculates evaluating lower urinary tract symptoms, nephrolithiasis burden, and prostate cancer risk. Key inputs include total psa. Scores guide initiating medical expulsive or alpha-blocker therapy, ordering renal imaging, or scheduling surgical intervention. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
The Beckman Coulter Prostate Health Index combines total PSA, free PSA and [-2]proPSA: phi = (p2PSA / fPSA) x sqrt(tPSA). Validated for men >=50 with PSA 4-10 ng/mL and non-suspicious DRE.
Clinical Indication
The Prostate Health Index (phi) is indicated for bedside clinical practice to support The Beckman Coulter Prostate Health Index combines total PSA, free PSA and [-2]proPSA: phi = (p2PSA / fPSA) x sqrt(tPSA). Validated for men >=50 with PSA 4-10 ng/mL and non-suspicious DRE.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with renal colic, hematuria, benign prostatic hyperplasia (BPH), or urogenital malignancies. Clinical application is indicated across Urology clinics, shock wave lithotripsy suites, and acute urologic surgical services.
Limitations & Contraindications
Serum PSA levels can be transiently elevated by acute prostatitis, urinary retention, or recent instrumentation.
Clinical Pearls & Action Plan
Obstructive urolithiasis complicated by upper urinary tract infection represents a surgical emergency requiring urgent decompression. Guideline pearl: In the pivotal trial a phi of 27.0 gave 31% specificity at 90% sensitivity; risk rises continuously with phi..
phi = (p2PSA [pg/mL] / fPSA [ng/mL]) x sqrt(tPSA [ng/mL]). NOTE the intentional unit mix: p2PSA in pg/mL, fPSA and tPSA in ng/mL.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| total_psa | float | Yes | Total PSA (ng/mL) |
| free_psa | float | Yes | Free PSA (ng/mL) |
| p2psa | float | Yes | [-2]proPSA (pg/mL) |
| age_years | integer | Yes | Age (years, >=50 for validated use) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–27 | Below operating point | phi <27 |
| 27–1000000000 | At/above operating point | phi >=27 |
Evidence-Based References (EBM)
- Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011;185(5):1650-1655.
- FDA approval 2012: phi for men >=50 years, tPSA 4-10 ng/mL, non-suspicious DRE.